Amarin shares surge after fish oil capsule showed benefits in trial

Amarin Corporation shares surged on Monday after the biopharmaceutical company’s fish oil capsule showed dramatic benefits in a clinical trial.

Amarin’s capsule, Vascepa, significantly reduced serious cardiovascular events compared to a placebo, according to Amarin’s trial results which looked at 8,179 statin-treated adults with elevated cardiovascular risk.

“We are delighted with these topline study results,” John Thero, president along with CEO of Amarin, said in a press Discharge. The company said the trial met the primary endpoint that has a 25 percent risk reduction.

Shares of Amarin were more than 300 percent higher in premarket trading Monday, around $12.40 a share. The stock had closed at $2.99 on Friday. Amarin was down more than 25 percent This specific year through Friday’s close.

Amarin will present the results at the 2018 Scientific Sessions of the American Heart Association in November.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

thirteen − 5 =